Identification | Back Directory | [Name]
H-ARG-ARG-ALA-ASN-ALA-LEU-LEU-ALA-ASN-GLY-VAL-GLU-LEU-ARG-ASP-OH | [CAS]
144796-71-4 | [Synonyms]
CB2450858 RRANALLANGVELRD TNF-α (31-45), human TNF-A (31-45) (HUMAN) TNF - α (31 - 45), human TNF-ALPHA (31-45) (HUMAN) TNF - ALFA (31 - 45), HUMAN TUMOR NECROSIS FACTOR-ALPHA (31-45) (HUMAN) tumor necrosis factor-α human fragment 31-45 TUMOR NECROSIS FACTOR-ALPHA FRAGMENT 31-45 HUMAN TuMor Necrosis Factor-alpha HuMan FragMent 31-45 ARG-ARG-ALA-ASN-ALA-LEU-LEU-ALA-ASN-GLY-VAL-GLU-LEU-ARG-ASP H-ARG-ARG-ALA-ASN-ALA-LEU-LEU-ALA-ASN-GLY-VAL-GLU-LEU-ARG-ASP-OH L-Aspartic acid,L-arginyl-L-arginyl-L-alanyl-L-asparaginyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-asparaginylglycyl-L-valyl-L-α-glutamyl-L-leucyl-L-arginyl- L-Aspartic acid, L-arginyl-L-arginyl-L-alanyl-L-asparaginyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-asparaginylglycyl-L-valyl-L-α-glutamyl-L-leucyl-L-arginyl- (9CI) | [Molecular Formula]
C69H122N26O22 | [MDL Number]
MFCD00214686 | [MOL File]
144796-71-4.mol | [Molecular Weight]
1667.87 |
Chemical Properties | Back Directory | [density ]
1.49±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
2.86±0.10(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
TNF-α (31-45), human is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis[1][2][3]. | [IC 50]
NF-κB | [storage]
Store at -20°C | [References]
[1] Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000 Aug 1;50(3):184-95. DOI:10.3390/ijms22052719 [2] Xi Rui, et al. RPS3 Promotes the Metastasis and Cisplatin Resistance of Adenoid Cystic Carcinoma. Front Oncol. 2022 Jun 30:12:804439. DOI:10.3389/fonc.2022.804439 [3] Jang DI, et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci. 2021 Mar 8;22(5):2719. DOI:10.3390/ijms22052719 |
|
|